TMRW Life Sciences

TMRW is a life sciences technology company setting new standards for transparency, safety, and accountability in IVF and cell management. TMRW's platform, the world's first automated cryo-management for eggs and embryos, provides a complete digital chain of custody fully integrated with a robotic storage and monitoring solution. This is in contrast to the manual and analog methods that have gone unchanged throughout the history of IVF. With TMRW's platform, clinics significantly reduce the chances of potentially devastating errors. The TMRW team includes celebrated innovators in fertility, embryology, cryo-management, automation, software development, and robotics.

TMRW is founded by Joshua Abram, Alan Murray, and Dr. Jeffrey Port in 2018 and is based in New York, New York.

TMRW Life Sciences headquartered in New York, New York, United States, North America, operates in the Software, Biotechnology, Life Science, Health Care sector. The company focuses on Software and has secured $17.4B in funding across 96 round(s). With a team of 101-250 employees, TMRW Life Sciences is actively contributing to advancements in Software. Their latest funding round, Series D - TMRW Life Sciences, raised $28.2M. Discover more about their projects, partnerships, and impact on our platform.